Abstract
Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Current Vascular Pharmacology
Title:Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update
Volume: 16 Issue: 2
Author(s): Yi-dong Wang, Zhen-jie Liu, Jun Ren and Mei-Xiang Xiang*
Affiliation:
- Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009,China
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Abstract: Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Export Options
About this article
Cite this article as:
Wang Yi-dong , Liu Zhen-jie , Ren Jun and Xiang Mei-Xiang *, Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update, Current Vascular Pharmacology 2018; 16 (2) . https://dx.doi.org/10.2174/1570161115666170413145705
DOI https://dx.doi.org/10.2174/1570161115666170413145705 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine MicroRNAs in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Extraction of Quantitative Anatomical Information from Coronary Angiographies
Current Bioinformatics microRNAs in Stroke Pathogenesis
Current Molecular Medicine Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships
Current Cardiology Reviews microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Normal Bicaudate Index by Aging
Current Medical Imaging MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery